Condition
Neuromyelitis Optica Spectrum Disorder (NMOSD) clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Neuromyelitis Optica Spectrum Disorder (NMOSD) clinical trials that are recruiting, at sites in 9 countries (most in United States (2), China (1), Australia (1)). By phase: Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 9Countries
Newest Neuromyelitis Optica Spectrum Disorder (NMOSD) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases | Phase 1 | Wuhan, Hubei | Recruiting | Apr 13, 2026 |
| HBI0101 CAR-T for refractory B‑cell autoimmune rheumatic diseases | Phase 1 | Jerusalem | Recruiting | Jul 25, 2025 |
| Wellness program to improve quality of life in NMOSD patients | — | New York, New York | Recruiting | Jan 17, 2025 |
| Safety of Ultomiris during pregnancy | — | Boston, Massachusetts and 6 other locations | Recruiting | Mar 15, 2024 |
All recruiting trials (4)
-
QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases
This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.
-
HBI0101 CAR-T for refractory B‑cell autoimmune rheumatic diseases
This will test a single infusion of HBI0101 CAR‑T cells in adults with severe, treatment‑resistant B‑cell autoimmune diseases such as SLE, systemic sclerosis, idiopathic inflammatory myopathy, rheumatoid arthritis, or primary progressive MS.
-
Wellness program to improve quality of life in NMOSD patients
This study is testing a wellness program to see if it can improve the quality of life for people with Neuromyelitis Optica Spectrum Disorder (NMOSD).
-
Safety of Ultomiris during pregnancy
This study looks at how safe Ultomiris is for pregnant women and their babies to see if it causes any problems during pregnancy and breastfeeding.
Related topics
Quick answers
How many Neuromyelitis Optica Spectrum Disorder (NMOSD) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 9 countries. The most sites are in United States (2 trials), China (1 trial), Australia (1 trial), France (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.